WG
SGMO

Winton Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Winton Group’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25,197
Closed -$227K – 1352
2021
Q3 		$227K Sell
25,197
-22,331
-47% -$221K 0.01% 1198
2021
Q2 		$569K Buy
47,528
+4,061
+9% +$46K 0.03% 841
2021
Q1 		$545K Buy
43,467
+11,654
+37% +$157K 0.03% 833
2020
Q4 		$496K Buy
31,813
+4,080
+15% +$47.8K 0.04% 795
2020
Q3 		$262K Sell
27,733
-62,032
-69% -$671K 0.01% 1284
2020
Q2 		$804K Buy
89,765
+59,597
+198% +$553K 0.02% 1055
2020
Q1 		$192K Sell
30,168
-77,374
-72% -$574K 0.01% 1264
2019
Q4 		$900K Buy
+107,542
New +$989K 0.01% 1096

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Winton Group's SGMO Position: Q4 2021 in Review

Winton Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2021, closing a stake of 25,197 shares — an estimated $227K sold.

Winton Group first reported a position in SGMO in Q4 2019 and held it in 8 quarters. The position peaked at $900K in Q4 2019. 193 funds tracked by Wall St. Rank hold SGMO as of Q4 2021.

  • Winton Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2021 after selling out during the quarter.
  • Winton Group sold 25,197 SANGAMO THERAPEUTICS INC shares in Q4 2021, an estimated $227K.
  • Winton Group first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 8 quarters.
  • Winton Group's SANGAMO THERAPEUTICS INC position peaked at $900K in Q4 2019.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.